Psilocybin

John Krystal, MD discusses the potential of ketamine and other psychedelics in treating psychiatric disorders, highlighting the antidepressant effects of ketamine and the development of drug combinations at Freedom Biosciences to extend ketamine's efficacy. The FDA's recent decision on MDMA-assisted therapy for PTSD has spurred further research into psychedelics for conditions like major depression, PTSD, migraine, and substance use disorders.

Congressional lawmakers seek public input on creating a regulatory framework for psychedelic therapies, emphasizing the need for inclusive, responsible, and ethical use, and considering the cultural practices of indigenous communities.

Drug shortages, including critical antibiotics, fever medications, and cancer treatments, highlight global supply chain issues and the need for improved health policies. The FDA rejected MDMA for PTSD treatment, with psilocybin next for treatment-resistant depression. Companion apps tested for alleviating loneliness. Advanced Clinical named one of Crain's Best Places to Work in Chicago 2024. Luke Forsthoefel's thought leadership article published in Pharmaceutical Executive magazine.

Psyence Biomed announces Phase IIb study for nature-derived psilocybin in Adjustment Disorder, expands pipeline into AUD and SUDs, and plans potential acquisition of Clairvoyant Therapeutics. Two Phase II data readouts expected in 2025.

Psyence Group announces successful site initiation visit for Psyence Biomed's Phase IIb study of nature-derived psilocybin for Adjustment Disorder in Palliative Care in Australia, partnering with Fluence and iNGENū CRO. The trial will evaluate two doses of psilocybin against a low-dose comparator in 87 patients.

Aaron Martin, a financial manager, found relief from depression and addiction through psychedelic treatments in Costa Rica, leading to significant lifestyle changes. The FDA's recent denial of MDMA for PTSD treatment highlights challenges in psychedelic therapy approval, though ongoing research at the University of Iowa explores psychedelics for alcoholism treatment. Experts emphasize the necessity of combining psychedelics with psychotherapy for effective mental health treatment.

A study from Emory University estimates 5.1-5.6 million Americans treated for depression could qualify for psilocybin-assisted therapy if approved by the FDA. The research, involving Emory, UW-Madison, and UC Berkeley, suggests 56-62% of treated patients could be eligible, highlighting significant potential demand. Challenges include FDA approval, insurance coverage, practitioner training, and regional healthcare access.

A study estimates 56-62% of U.S. depression patients, or 5.1-5.6 million individuals, could qualify for psilocybin therapy if approved by the FDA, highlighting the need for further research and preparation for equitable treatment delivery.

A study estimates 5.1 to 5.6 million Americans receiving depression treatment could qualify for psilocybin therapy if approved by the FDA, based on criteria from recent clinical trials.

Over 5 million Americans could benefit if the FDA approves psilocybin as a depression treatment, according to researchers. The study estimates 56% to 62% of currently treated depression patients could be eligible for psilocybin therapy, potentially reaching 5.1 to 5.6 million people. The number could increase if untreated individuals opt for the treatment. The findings highlight the need for discussions on insurance coverage, regulatory conditions, and trained professionals to administer the treatment safely.